Screener
Mineralys Therapeutics, Inc. MLYS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
FAQ
- What is Mineralys Therapeutics, Inc.'s return on equity?
- Mineralys Therapeutics, Inc. (MLYS) reported return on equity of -31% in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s return on equity changed year-over-year?
- Mineralys Therapeutics, Inc.'s return on equity increased by 45.0% year-over-year, from -56.3% to -31%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Mineralys Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude